{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:50:38Z","timestamp":1761177038319,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.tracli.2022.08.144","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T02:24:48Z","timestamp":1661221488000},"page":"11-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Don\u2019t neglect the rare adverse event with intravenous immunoglobulin: Hemolytic anemia"],"prefix":"10.1016","volume":"30","author":[{"given":"\u0130smail","family":"Ucar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut Bakir","family":"Koyuncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Alper","family":"Solmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil Can","family":"Ugurludogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seda","family":"Mercan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tufan","family":"Unal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Semir","family":"Mazman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erden","family":"Atilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2022.08.144_b0005","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.tracli.2022.08.144_b0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/tme.12083","article-title":"Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature","volume":"24","author":"Desborough","year":"2014","journal-title":"Transfus Med"},{"key":"10.1016\/j.tracli.2022.08.144_b0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJM197208172870719","article-title":"Blood-group antibodies in human immune serum globulin","volume":"287","author":"Case","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2022.08.144_b0020","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1111\/trf.13096","article-title":"Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment","volume":"55","author":"Taylor","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2022.08.144_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1546-0096-10-10","article-title":"Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases","volume":"10","author":"Berard","year":"2012","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.tracli.2022.08.144_b0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1160\/TH03-10-0650","article-title":"IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life","volume":"91","author":"Bussel","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tracli.2022.08.144_b0035","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1537-2995.2008.01721.x","article-title":"Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis","volume":"48","author":"Daw","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2022.08.144_b0040","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1111\/trf.13087","article-title":"Anti-A and anti-B: what are they and where do they come from?","volume":"55","author":"Branch","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2022.08.144_b0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.transci.2011.11.004","article-title":"Hemolysis upon intravenous immunoglobulin transfusion","volume":"46","author":"Padmore","year":"2012","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/j.tracli.2022.08.144_b0050","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2215\/CJN.04540709","article-title":"Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients","volume":"4","author":"Kahwaji","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.tracli.2022.08.144_b0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000354893","article-title":"Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk","volume":"38","author":"Dantal","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.tracli.2022.08.144_b0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IJCTM.S94329","article-title":"Intravenous immunoglobulin-associated hemolysis: risk factors, challenges, and solutions","volume":"4","author":"Muhajir","year":"2016","journal-title":"Int J Clin Transf Med"},{"key":"10.1016\/j.tracli.2022.08.144_b0065","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1111\/trf.13088","article-title":"Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products","volume":"55","author":"Hoefferer","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2022.08.144_b0070","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1111\/trf.13198","article-title":"Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012","volume":"55","author":"Berg","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2022.08.144_b0075","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/labmed\/lmaa019","article-title":"Intravenous immunoglobulin-associated hemolytic anemia","volume":"51","author":"Jacobs","year":"2020","journal-title":"Lab Med"},{"key":"10.1016\/j.tracli.2022.08.144_b0080","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1111\/trf.13097","article-title":"The role of inflammation in intravenous immune globulin-mediated hemolysis","volume":"55","author":"Pendergrast","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2022.08.144_b0085","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1111\/trf.13090","article-title":"Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports","volume":"55","author":"Padmore","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2022.08.144_b0090","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2141.2011.08784.x","article-title":"Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study","volume":"154","author":"Garbe","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782022002373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782022002373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:42:14Z","timestamp":1761129734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782022002373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1246782022002373"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2022.08.144","relation":{},"ISSN":["1246-7820"],"issn-type":[{"type":"print","value":"1246-7820"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Don\u2019t neglect the rare adverse event with intravenous immunoglobulin: Hemolytic anemia","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2022.08.144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}